Event Participants
Executives
4
Sanjay Agarwal (Group CFO), Atul Gupta (CEO, CSM Ag Chem), Jagresh Rana (Global CEO, PI AG Sciences), Mayank Singhal (Vice Chairman & MD)
Analysts
8
Abhijit (Analyst), Ankur Periwal (Axis Capital), Priju (Antique Stock Broking), Rohit Nagraj (360 ONE Capital), Sanjay Kumar (ithought PMS), Siddharth Gadekar (Equirus), Surya Narayan Patra (PhillipCapital India), Tejas Pradhan (Citigroup)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹17,023 million | Q1 FY27 reported revenue amid softness from cyclical headwinds and global disruptions; exports facing demand challenges while domestic grew |
| Gross Margin | 57% | Healthy gross margin supported by disciplined execution; monitoring raw material price volatility |
| EBITDA | ₹3,693 million (22% margin) | Continued significant investments in future growth platforms; R&D investments contribute 3–4% of revenue |
| Net Working Capital Reduction | 19 days improvement | Released ₹300 crores of cash despite challenging environment; team driving working capital excellence |
| Net Cash | ₹38 billion | Strong debt-free balance sheet providing resilience and flexibility for strategic investments |
| Export Volume Growth | -8% volume, -12% value | Contracting global crop protection industry; soft commodity prices and muted crop economy recovery |
| Domestic Volume Growth | +12% volume, +3% revenue | Growth despite El Niño, heat waves, delayed sowings; biologicals grew aggressively at 50% |
| Distribution Network | 15,000+ distributors, 1.5 lakh retailers | Deep market presence creating resilient channel network and strong partner relationships |
| New Product Contribution (CSM) | 16–18% of revenue | Contribution from products commercialized in recent years |
| Order Book | $1.2 billion | Running order book position broadly stable sequentially |
| Contract Asset | ~₹750 crores | June 2026 contract asset position |
Geographic & Segment Commentary
Ag Chem Export (CSM): Operating environment remains challenging with soft commodity prices, muted crop economics recovery, and geopolitical pressures including tariffs. Consumption bankers exert pressure on growth and pricing. Despite near-term challenges, the company commissioned one of the world's largest flow chemistry plants for advanced hazardous chemistry, positioning for sustainable manufacturing with superior process control.
Domestic Agribusiness: Delivered 12% volume growth translating to 3% revenue growth despite challenging operating environment with El Niño, heat waves, and delayed sowings. Sowing has now picked up and is at par with last year. Flagship brands including Nominee Gold, Brofreya, and Biovita maintained leadership positions. Biologicals achieved aggressive 50% growth with three-year CAGR of 15%.
Pharma (CRDMO): Early positive signs in transforming into a differentiated CRDMO organization. Couple of interesting inquiries moving into commercial phase. Capability build-out strengthening with Center of Excellence for Drug Discovery in Hyderabad and CRO facilities, plus QC lab approved by regulators at Italian site. Long-term ambition is fully integrated CRDMO platform requiring patience, capability building, and customer trust.
Global Biologicals: Strong traction across Brazil, Mexico, Europe, and US supported by 500+ field trials and 1,000+ grower engagements. New foliar application nematicide, first of its kind in the industry, performing at par or better than chemical alternatives. Unique flexibility for seed treatment, in-furrow, and foliar application provides significant differentiation.
Electronics & Specialty Chemicals: Inquiries and commercialization showing positive trajectory with investments tracking on plan. Commercial block operational with supplies started under new technology. Pursuing differentiated approach rather than commoditized lower-end value chain.
Company-Specific & Strategic Commentary
Pioxaniliprole Launch: India-discovered insecticide (first for Indian farmers going global) set to launch in domestic market soon, awaiting regulatory approvals. Expect launch within the year for India; global geography registrations planned for next year and year after. Demonstrates capability to take innovation from India to the world.
R&D Investment Philosophy: R&D expenses increased from ~₹100 crores to ~₹400 crores over last 3–4 years, remaining at 3–4% of revenue. Management explicitly positions R&D as value creation, not cost, benchmarking against global innovation standards.
New Product Pipeline: ~90 molecules under various stages of progress with ~60 at advanced stages. Launch plan for FY27 includes agrochemical products, 2 products in electronic chemicals, and 1–2 in pharma/health sciences. Pipeline spans Ag Chem, biologicals (2–3 more launches lined up), and electronics.
Flow Chemistry Capability: Commissioned one of the world's largest flow chemistry plants enabling safer hazardous chemistry handling, superior process control, and cost-efficient production. Supports futuristic product requirements with stringent regulatory compliance.
Pharma IDD Partnerships: Exclusive partnership signed for integrated drug discovery with one biotech partner. Services include chemistry, process capabilities, and biological evaluation. Two to three additional opportunities under evaluation, building front-end capability that leads to CRO/CDMO revenue.
Biological Nematicide Potential: Brazil nematicide market estimated at ~$750 million with ~5 million hectares planted. Management indicates double-digit market share achievable over 5–10 years with market also growing. US launch underway focusing on field crops (corn, soybean) and fruit/vegetable markets.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY27 Revenue Growth | Low single digits (reaffirmed) | Positive trajectory maintained; depends on cycle and industry recovery—could go one way or other; expects better H2 driven by export recovery |
| EBITDA Margin (FY27) | ~24% | Reflects continued investment in future growth platforms including new businesses and R&D |
| Exports Recovery | H2 FY27 recovery expected | Supported by new product launches and gradual scale-up of pharma and global biologicals |
| CapEx | ₹700–800 crores for FY27 | Q1 investment ~₹250 crores across three verticals: existing manufacturing, new verticals, and innovation-led approaches |
| Domestic Outlook | Optimistic for coming quarters | New product launches planned and improving monsoon conditions support growth outlook |
| Dicloromezotiaz Launch | This coming season | New generation product for Diamondback Moth; expected to be 3-digit revenue product over 5–7 years in Indian context |
Risks & Constraints
| Risk | Context |
|---|---|
| Industry Pricing Pressure | Demand cycle challenges, soft commodity prices, and weak consumption patterns create pricing pressure across Ag Chem domestically and globally. Input cost inflation further compresses margins. Management expects this cycle to break given historically unprecedented duration. |
| Geopolitical & Tariff Disruptions | Rising costs from geopolitical issues and tariff pressures affecting export competitiveness. Currency benefits are shared through pass-through model rather than retained, limiting margin buffer from rupee depreciation. |
| New Business Execution Risk | Subsidiary EBIT losses (~₹120 crores) primarily from global biologicals market development investment and pharma ramp-up. These investments are front-loaded and expected to continue for several quarters before revenue scales. |
| Delayed Sowing & Weather | El Niño, heat waves, and delayed sowings impacted pre-placement sales of chemicals. While sowing has recovered to par with last year, erratic weather continues to pose risk to crop consumption patterns. |
| Monsoon Dependency | Domestic agribusiness remains exposed to monsoon variability; management remains watchful of climatic situations impacting crop and consumption. |
| Small Portfolio Volatility in Pharma | CRDMO revenue volatility is higher at current small portfolio scale; delays in order conversion can shift revenue between quarters. |
Q&A Highlights
Molecular Pipeline & Product Launches
- Question: How should we view the 90-molecule pipeline across segments? How many product launches in FY27? (Ankur Periwal, Axis Capital)
- Answer: The pipeline is a funnel approach with ~70 projects, majority in Ag Chem, plus electronic chemicals and biologicals. No segment-wise breakup disclosed. Launches: multiple Ag Chem products, 2 electronic chemicals, and 1–2 pharma/health sciences products this year. (Mayank Singhal)
Pricing Pressure Assessment
- Question: Is pricing pressure product-specific or general trend? (Ankur Periwal, Axis Capital)
- Answer: Challenged demand cycles, soft commodity prices, and weak consumption patterns drive pricing pressure. Generic, large-volume products face more pressure at lower end of value chain. Better clarity expected from Q2 as global commodity prices firm up. (Mayank Singhal)
FY27 Guidance & Margin Outlook
- Question: Reaffirm FY27 revenue growth guidance? How to model margins? (Tejas Pradhan, Citigroup)
- Answer: Maintained low single-digit growth trajectory guidance. Margins depend on geopolitical situation, commodity prices, and logistics. Focus is on sustaining gross margins through optimization and agility rather than relying solely on product mix. (Mayank Singhal)
Pioxaniliprole Launch Timelines
- Question: When can we expect commercial launch domestically and in other geographies? (Rohit Nagraj, 360 ONE Capital)
- Answer: Domestic launch expected within the year pending regulatory approvals. Other geographies: one market next year, another the year after, based on local regulatory data. (Mayank Singhal)
Currency Benefit Pass-Through
- Question: Why didn't rupee depreciation benefit show in export revenue given 13% depreciation vs 8% volume decline? (Surya Narayan Patra, PhillipCapital India)
- Answer: PI operates a pass-through model where currency benefits are shared with partners. Business is focused on product and margin sustainability rather than currency gains. Complex risk management approach balances value benefits and margins. (Mayank Singhal)
Electronic Chemicals Commercialization
- Question: What does "commercialized" mean for electronic chemicals after years of development? (Siddharth Gadekar, Equirus)
- Answer: Commercial block operational with commercial supplies started using new technology. Gestation is long in this sector with dynamic technology requirements. Strategy is differentiated high-tech approach rather than commoditized entry. (Mayank Singhal)
Brazil Nematicide Market Potential
- Question: What market share can be achieved in Brazil's $750 million nematicide market? (Sanjay Kumar, ithought PMS)
- Answer: Double-digit market share is achievable without challenge based on competitive intelligence. Timeline of 5–10 years for product development, though acceleration expected as market grows. Product offers unique foliar application flexibility unavailable in chemical alternatives. (Mayank Singhal, Jagresh Rana)
Pharma CRDMO Strategy & IDD Partnership
- Question: Talk about the exclusive integrated drug discovery partnership and ability to sign more deals. (Sanjay Kumar, ithought PMS)
- Answer: IDD services include chemistry, process capabilities, and biological evaluation. One partner locked in, two to three more opportunities under evaluation. This front-end capability attracts customers toward manufacturing revenue. (Mayank Singhal)
Key Takeaway
PI Industries delivered a challenging Q1 FY27 with revenue of ₹17,023 million, maintaining healthy 57% gross margins and 22% EBITDA despite industry-wide headwinds from soft commodity prices, geopolitical disruptions, and domestic weather-related sowing delays. Domestic business demonstrated resilience with 12% volume growth, including 50% growth in biologicals, while exports declined 12% in value terms on 8% volume contraction. The company continues aggressive strategic investments—R&D at 3–4% of revenue, ₹250 crores CapEx in the quarter, and significant subsidiary investment in global biologicals market development—positioning for future growth across agrochemical innovation (pioxaniliprole domestic launch imminent), pharma CRDMO expansion with a new IDD partnership, and electronics chemicals commercialization. Management reaffirmed low single-digit FY27 growth guidance with EBITDA margin around 24%, expecting H2 export recovery driven by new product launches. Key watch points include industry pricing pressure sustainability, domestic monsoon trajectory, and the pace of biologicals adoption across Brazil, US, and Mexico markets where the company's novel foliar-application nematicide targets double-digit market share in a $750 million Brazilian market.